Download PDF
Semin Thromb Hemost 2003; 29(1): 069-076
DOI: 10.1055/s-2003-37941
Copyright © 2003 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Immune Tolerance Induction in Hemophilia A: A Review

Guglielmo Mariani1 , Sergio Siragusa2 , Barbara L. Kroner3
  • 1Professor, Hematology and BMT Unit, University of Palermo Medical School, Palermo, Italy
  • 2Hematology and BMT Unit, University of Palermo Medical School, Palermo, Italy
  • 3Research Triangle Institute, Rockville, Maryland
Further Information

Publication History

Publication Date:
17 March 2003 (online)

    Permissions and Reprints

ABSTRACT

In this article, a comparative analysis of the data stemming from the studies conducted in the field of immune tolerance treatment (ITT) of hemophilia A was attempted. Comparisons are difficult because previous studies differ in many respects, including the dosage of factor (F) VIII, the number of FVIII administrations per day, the association with immunosuppressive drugs (prednisone, cyclophosphamide), and, most importantly, the definition of success in terms of the reacquisition of tolerance. However, a number of variables consistently influenced outcome: the inhibitor titer, either the maximum one or the one assayed before immune tolerance (IT) start and age. As to the FVIII dose, results are contrasting, even though the overall impression is that high dosages are associated with higher success rates. Treatment duration analyses appear to be fairly consistent in all the studies, with 1 year as the crucial time period useful in predicting outcome. Preliminary data suggest that concentrates containing von Willebrand factor may increase the success rate and allow patients refractory to IT procedures carried out with ultrapure or recombinant concentrates to become tolerant in the end. These data need to be formally confirmed in trials that compare the different brands. In the studies published so far, a common language and widely accepted definitions of the variables have emerged, which are important in setting up the controlled trials and improving the comparison among published data.

KEYWORD

FVIII - FVIII inhibitors - immune tolerance - hemophilia A - factor VIII concentrates

REFERENCES

  • 1 Scandella D, Mahoney S D, Mattingly M. et al . Epitope mapping of human FVIII inhibitor antibodies by deletion analysis of FVIII fragments expressed in Escherichia coli .  Proc Natl Acad Sci USA . 1988;  85 6152-6156
    CrossrefPubMedGoogle Scholar
  • 2 Prescott R, Nakai H, Saenko E L. et al . The inhibitory antibody response is more complex in hemophilia A patients than in most non-hemophiliacs with fVIII autoantibodies.  Blood . 1997;  89 3663-3671
    PubMedGoogle Scholar
  • 3 Briet F, Rosendaal F R, Kreuz W. et al . High titer inhibitors in severe haemophilia A. A meta-analysis based on eight long-term follow up studies concerning inhibitors associated with crude or intermediate purity factor VIII products.  Thromb Haemost . 1994;  72 162-164
    PubMedGoogle Scholar
  • 4 Ehrenforth S, Kreutz W, Scharrer I. et al . Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs.  Lancet . 1992;  339 594-598
    CrossrefPubMedGoogle Scholar
  • 5 Mariani G, Kroner B. Immune tolerance in hemophilia with factor VIII inhibitors: predictors of success.  Haematologica . 2001;  86 1186-1193
    PubMedGoogle Scholar
  • 6 Brackmann H H, Gormsen J. Massive factor VIII infusion in hemophiliacs with factor VIII inhibitor, high responder (Letter).  Lancet . 1977;  2 933
    PubMedGoogle Scholar
  • 7 Brackmann H H. Induced immune tolerance in factor VIII inhibitor patients.  Progr Clin Biol Res . 1984;  150 181-195
    PubMedGoogle Scholar
  • 8 Brackmann H H, Oldenburg J, Schwaab R. Immune tolerance for the treatment of factor inhibitors-twenty years' "Bonn protocol." Vox Sang .  1996;  70 30-35
    PubMedGoogle Scholar
  • 9 Oldenburg J, Schwaab R, Brackmann H H. Induction of immune tolerance in haemophilia A inhibitor patients by the "Bonn Protocol": predictive parameter for therapy duration and outcome.  Vox Sang . 1999;  77 49-54
    CrossrefPubMedGoogle Scholar
  • 10 Gruppo R A, Valdez R P, Stout R D. Induction of immune tolerance in patients with hemophilia A and inhibitors.  Am J Pediatr Hematol Oncol . 1992;  14 82-87
    PubMedGoogle Scholar
  • 11 Ewing N, Sanders N L, Dietrich S L, Kasper C K. Induction of immune tolerance to factor VIII in hemophiliacs.  JAMA . 1988;  259 65-68
    CrossrefPubMedGoogle Scholar
  • 12 Mauser-Bunschoten E P, Nieuwerhuis H K, Rosendaal G, van den Berg M H. Low dose immune tolerance induction in hemophilia A patients with inhibitors.  Blood . 1995;  86 983-988
    PubMedGoogle Scholar
  • 13 Berntorp E, Astermark J, Carlborg E. Malmoe protocol update.  Haematologia . 2000;  85 48-51
    PubMedGoogle Scholar
  • 14 Di Michele D, Kroner B. The North American Immune Tolerance Registry: practices, outcomes, outcome predictors.  Thromb Haemost . 2002;  87 52-57
    PubMedGoogle Scholar
  • 15 Brackmann H H, Lenk H, Scharrer I, Auerswald G, Kreuz W. German recommendations for immune tolerance therapy in type A haemophiliacs with antibodies.  Haemophilia . 1999;  5 203-206
    CrossrefPubMedGoogle Scholar
  • 16 Mariani G, Ghirardini A, Bellocco R. Immune tolerance in hemophilia-principal results from the International Registry.  Thromb Haemost . 1994;  72 155-158
    PubMedGoogle Scholar
  • 17 Mariani G, Kroner B. International Immune Tolerance Registry, 1997 update.  Vox Sang . 1999;  77 25-27
    CrossrefPubMedGoogle Scholar
  • 18 Di Michele M D, Kroner B. Analysis of the North American Immune Tolerance Registry (NAITR) 1993-1997; current practice implications.  Vox Sang . 1999;  77 31-32
    CrossrefPubMedGoogle Scholar
  • 19 Di Michele D, Kroner B. The maintenance of tolerance after successful immune tolerance induction in hemophilia A and B: The North American Registry.  Haematologica . 2000;  85 40-44
    PubMedGoogle Scholar
  • 20 Lenk H. The German National Immune Tolerance Registry, 1997 update.  Vox Sang . 1999;  77 28-30
    CrossrefPubMedGoogle Scholar
  • 21 Lenk H. The German Registry of immune tolerance treatment in hemophilia-1999 update.  Haematologica . 2000;  85 45-47
    PubMedGoogle Scholar
  • 22 Kroner B L. Comparison of the International Immune Tolerance Registry and of the North American Immune Tolerance Registry.  Vox Sang . 1999;  77 33-37
    CrossrefPubMedGoogle Scholar
  • 23 Haya S, Lopez M F, Aznar J A, Battle J, for the Spanish Immune Tolerance Group. Immune tolerance treatment in haemophilia patients with inhibitors: the Spanish Registry.  Haemophilia . 2001;  7 154-159
    CrossrefPubMedGoogle Scholar
  • 24 Shima M, Nakai H, Scandella D. et al . Common inhibitory effect of human anti-C2 domain inhibitor alloantibodies on factor VIII binding to von Willebrand factor.  Br J Haematol . 1995;  91 714-721
    PubMedGoogle Scholar
  • 25 Berntorp E. Immune tolerance induction: recombinant versus human derived product.  Haemophilia . 2001;  7 109-113
    CrossrefPubMedGoogle Scholar
  • 26 Gensana M, Altisent C, Aznar J A. et al . Influence of von Willebrand factor on the reactivity of human factor VIII inhibitors with FVIII.  Haemophilia . 2001;  7 369-374
    CrossrefPubMedGoogle Scholar
  • 27 Kreuz W, Joseph-Steiner J, Mentzer D. et al . Successful immune tolerance therapy of FVIII-inhibitor in children after changing from high to intermediate purity FVIII concentrate. Presented at the 40th Annual Meeting of the GTH, Interlaken 1996 (Abst).  Ann Hematol. 1996;  72 339
    PubMedGoogle Scholar
  • 28 Battle J, Lopez M F, Brackmann H H. et al . Induction of immune tolerance with recombinant factor VIII in hemophilia A patients with inhibitors.  Haemophilia . 1999;  5 431-435
    CrossrefPubMedGoogle Scholar
  • 29 Rocino A, deBiasi R. Successful immune tolerance treatment with monoclonal or recombinant factor VIII concentrates in high responding inhibitor patients.  Vox Sang . 1999;  77 65-69
    PubMedGoogle Scholar
  • 30 Hay C RM. Immune tolerance induction: prospective clinical trials.  Haematologica . 2000;  85 52-56
    PubMedGoogle Scholar
      >